All In Biotech

Drug Trial Radar · NCT06723080

Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

480

Planned (sponsor's estimate)

Start

Dec 30, 2024

Primary completion

Aug 30, 2027

Study completion Aug 30, 2027

Sponsor

Sponsor type
Industry
First posted
Dec 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study

Conditions

  • Moderate to Severe Atopic Dermatitis

Interventions

  • VC005 low dose groupDrug

    VC005 low dose group repeat administration

  • VC005 high dose groupDrug

    VC005 high dose group repeat administration

  • VC005 Placebo groupDrug

    VC005 Placebo group repeat administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects achieving at least a 75% reduction in Eczema Area and Severity Index (EASI 75) from Baseline at Week 16Time frame: week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese Academy of Medical Sciences Hospital for Skin Diseases

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.